SWISS MEDICA - Belgrade / Stem Cells Treatment Clinic Swiss Medica Belgrade

Swiss Medica describes a Belgrade hospital opened in 2024 with five buildings and residential patient support. Its official materials promote cell-based treatment programs; provider descriptions of experimental or investigational approaches must be distinguished from independently established efficacy for a particular diagnosis.

Swiss Medica describes a hospital opened in Belgrade in 2024. Its official facility page identifies five buildings on a three-hectare site and a total developed area of ten thousand square meters. The provider presents inpatient and outpatient services alongside residential support for people attending its treatment programs. These are provider-reported facility details, distinct from independent evidence about clinical outcomes.

The organization’s FAQ states that it was founded in Switzerland in 2011 and moved its clinical facilities to Serbia in 2016. It describes the new Belgrade hospital as its headquarters and separately identifies a Slovenian location focused on rehabilitation and post-treatment care. The Swiss origin of the business is therefore different from the current country where the described hospital operates.

The Belgrade facility presentation includes patient accommodation, procedure areas, dining and places for rest. It also describes diagnostic resources and a laboratory within the organization. These features support a description of the physical and residential setting; they do not establish an intensive-care department, a complete licensed bed total or an independently audited count of physicians.

The travel and assistance page describes a personal medical adviser, transfers, meals adapted to dietary needs and translation involving English. It presents examinations, procedures and accommodation as components of an individually arranged program. These are organizational and logistical claims made by the provider, not proof that all treatment components are clinically effective or appropriate for every diagnosis.

Swiss Medica promotes cell-based and regenerative treatment programs for several neurological and other conditions. Such programs require particular care in how they are described. The provider’s own account of a treatment, laboratory or research ambition does not establish regulatory approval for every indication, comparative efficacy or a cure. This profile therefore identifies the service category without adopting claims that experimental or investigational approaches are established routine treatment.

The FAQ provides routes to request certificates, arrange a virtual facility tour and contact the medical team. Its legal and professional assertions remain the provider’s statements rather than an independently completed regulatory audit. The official facility and logistics pages support the hospital’s location, reported building count and patient-support arrangements. They are kept separate from the evidence needed to assess a specific intervention, its risks, authorization and expected benefit.

The institution reports the following clinical and infrastructure information: outpatient care: Yes; buildings: 5 (Belgrade hospital announced in 2024.). The scope and reporting period remain those of the linked institutional sources.